Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter

Journal of Neurochemistry

Volumn 69, Issue 3, 1997, Pages 1322-1325

  Gainetdinov, Raul R ^a,b   Fumagalli, Fabio ^a,c   Jones, Sara R ^a   Caron, Marc G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Dopamine transporter; Glial fibrillary acidic protein; Microdialysis; MPP+; MPTP neurotoxicity

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; MALE; MICRODIALYSIS; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0030877835     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.69031322.x     Document Type: Article

References (24)

1. Chiang C. S., Stalder A., Samimi A., and Campbell I. L. (1994) Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice. Dev. Neurosci. 16, 212-222.
2. Chiueh C. C., Huang S.-J., and Murphy D. L. (1992) Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse 11, 346-348.
3. Chomczynski P. and Sacchi N. (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162, 156-159.
4. Eng L. F. (1985) Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J. Neuroimmunol. 8, 203-214.
5. Francis J. W., Von Visger J., Markelonis G. J., and Oh T. H. (1995) Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol. 17, 7-12.
6. Franklin K. B. J. and Paxinos G. (1996) The Mouse Brain in Stereotoxic Coordinates. Academic Press, San Diego.
7. Fumagalli F., Jones S. R., Caron M. G., Seidler F. J., and Slotkin T. A. (1996) Expression of mRNA coding for the serotonin transporter in aged vs. young brain: differential effects of glucocorticoids. Brain Res. 719, 225-228.
8. Giovanni A., Sonsalla P. K., and Heikkila R. E. (1994) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther. 270, 1008-1014.
9. Giros B., Jaber M., Jones S. R., Wightman R. M., and Caron M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
10. Heikkila R. E., Manzino L., Cabbat F. S., and Duvoisin R. C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467-469.
11. Jaber M., Jones S. R., Bosse R., Giros B., and Caron M. G. (1996) Dramatic regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Soc. Neurosci. Abstr. 22, 1576.
12. Javitch J. A., D'Amato R. J., Strittmatter S. M., and Snyder S. H. (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82, 2173-2177.
13. Kopin I. J. (1992) Features of the dopaminergic neurotoxin MPTP. Ann. NY Acad. Sci. 648, 96-104.
14. + toxicity encodes a vesicular amine transporter. Cell 70, 539-551.
15. + on the release of serotonin and 5-hydroxyindoleacetic acid from rat striatum in vivo. Eur. J. Pharmacol. 166, 49-55.
16. + (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine-, and serotonin-containing neurons. Eur. J. Pharmacol. 136, 31-36.
17. O'Callaghan J. P., Miller D. B., and Reinhard J. F. Jr. (1990) Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 521, 73-80.
18. Pifl C., Giros B., and Caron M. G. (1993) Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J. Neurosci. 13, 4246-4253.
19. Pileblad E., Fornstedt B., Clark D., and Carlsson A. (1985) Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine metabolism in mouse and rat striatum. J. Pharm. Pharmacol. 37, 707-712.
20. Ramsay R. R. and Singer T. P. (1986) Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261, 7585-7587.
21. Reinhard J. F. Jr., Miller D. B., and O'Callaghan J. P. (1988) The neurotoxicant MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) increases glial fibrillary acidic protein and decreases dopamine levels of the mouse striatum: evidence for glial response to injury. Neurosci. Lett. 95, 246-251.
22. +-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. J. Pharmacol. Exp. Ther. 245, 858-866.
23. Snyder S. H. and D'Amato R. J. (1986) MPTP, a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 36, 250-258.
24. Tipton K. F. and Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206.